Object reference not set to an instance of an object. Online Stock Broker - Stock Broking, Best Share Bazaar Brokers In India
Close
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Budget News

  • Sensex slides 514 pts; pharma shares underpressure
  • May 07,2024  14:41
  • The key equity indices traded with significant losses in mid-afternoon trade. The Nifty traded below the 22,300 level after hitting the day's high of 22,499.05 in early trade. Pharma shares witnessed profit booking after advancing in the past three consecutive trading sessions.

    At 14:30 IST, the barometer index, the S&P BSE Sensex slipped 513.6 points or 0.70% to 73,381.94. The Nifty 50 lost 172.15 points or 0.77% to 22,270.55.

    The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index dropped 2.02% and the S&P BSE Small-Cap index fell 1.69%.

    The market breadth was weak. On the BSE, 971 shares rose and 2,805 shares fell. A total of 118 shares were unchanged.

    Politics:

    On 7 May 2024, the Lok Sabha elections will enter their third phase with voting in 96 parliamentary constituencies across 12 states such as Gujarat, Karnataka, Madhya Pradesh, Maharashtra, Uttar Pradesh, and West Bengal. The BJP is seeking a third consecutive term, facing opposition from a coalition named the Indian National Developmental Inclusive Alliance (INDIA), which includes the Congress party. This round is part of a seven-phase election process running from April 19 to June 1, with the final election results scheduled to be revealed on June 4.

    Buzzing Index:

    The Nifty Pharma index slipped 2.12% to 18,796.40. The index rallied 1.30% in past three consecutive trading sessions.

    Lupin (down 5.46%), Aurobindo Pharma (down 4.36%), Zydus Lifesciences (down 3.44%), Ipca Laboratories (down 3.2%), J B Chemicals & Pharmaceuticals (down 3.11%), Torrent Pharmaceuticals (down 3.1%), Mankind Pharma (down 2.97%), Cipla (down 2.63%), Glenmark Pharmaceuticals (down 2.6%) and Granules India (down 2.56%) declined.

    Lupin slipped 5.46%. The pharma major?s consolidated net profit surged 52.33% to Rs 359.43 crore in the quarter ended March 2024 as against Rs 235.96 crore during the previous quarter ended March 2023. Sales jumped by 13.04% to Rs 4,895.11 crore in the quarter ended March 2024 as against Rs 4330.30 crore during the previous quarter ended March 2023.

    Numbers to Track:

    The yield on India's 10-year benchmark federal paper rose 0.17% to 7.120 as compared with previous close 7.108.

    In the foreign exchange market, the rupee is edged higher against the dollar. The partially convertible rupee was hovering at 83.5050, compared with its close of 83.5200 during the previous trading session.

    MCX Gold futures for 5 June 2024 settlement lost 0.29% to Rs 71,165.

    The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.14% to 105.20.

    The United States 10-year bond yield fell 0.62% to 4.459.

    In the commodities market, Brent crude for July 2024 settlement gained 31 cents or 0.37% to $ 83.64 a barrel.

    Stocks in Spotlight:

    Route Mobile dropped 4.98% after the company?s consolidated net profit fell 13.3% to Rs 88.10 crore in Q4 FY24 as compared with Rs 105.74 crore posted in Q3 FY24. Revenue from operations increased 0.83% YoY to Rs 1017.03 crore in Q4 FY24.

    Gujarat Fluorochemicals slipped 5.20% after the company?s consolidated net profit tumbled 69.58% to Rs 100.97 crore in Q4 FY24 as against Rs 331.88 crore recorded in Q4 FY23. Revenue from operations fell 23% year on year (YoY) to Rs 1,133.03 crore in quarter ended 31 March 2023.

    Powered by Capital Market - Live News

Economy News
Global News

Follow us:

  • fb icon
  • Twitter icon
  • Linkedin
  • you tube
  • Instagram

Disclaimer:

SMC Global Securities Ltd | CIN : L74899DL1994PLC063609 | Registered Office: 11/6B, Shanti Chamber, Pusa Road, Delhi-110005. | Tel +91-11-30111000 | Compliance Officer: Mr. Ashok Kumar Aggarwal | Tel 011-30111000 Extn. 170 | Email:-aka@smcindiaonline.com| Customer Care Email –smc.care@smcindiaonline.com| Complaint Email –igc@smcindiaonline.com| website: www.smctradeonline.com

SEBI Reg. No. INZ000199438, Member: NSE (07714), BSE (470), MSEI (1002), MCX (8200) & NCDEX (00021). DP SEBI Regn. No. CDSL/NSDL-IN-DP-130-2015, SMC Research Analyst Registration- INH100001849, Mutual Funds Distributor ARN No. 29345. •Insurance services are offered through SMC Insurance Brokers Pvt. Ltd. IRDAI Regn. No: DB 272/04 License No. 289 Valid upto 27/01/2026. • Real Estate Advisory services are offered through SMC Real Estate Advisors Pvt. Ltd.

Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Fund investments are subject to market risks. Read all scheme related documents carefully. PMS is not offered in commodity derivative segment. Insurance is the subject matter of solicitation. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise.The securities are quoted as an example and hot as a recommendation.

By submitting your details to SMC, you are authorizing us to send promotional communication through Call/Email/SMS/Whatsapp even though you may be registered under DND.

OUR OTHER WEBSITES Go
IMPORTANT LINKS Go
QUICK LINKS
Go

Toll-free : 1800-11-0909
Email: contact@smctradeonline.com

Sitemap
Plus Minus 
Copyright ©2016-2024 SMC. All Rights Reserved | Disclaimer | Privacy Policy | Copyright| Testimonials| Sitemap| Grievance|Terms And Conditions| design agency: triverse| Powered by C-MOTS Infotech (ISO 9001:2015 certified)

Open my trading account now!  X 

* All fields are compulsory